A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy

American Heart Journal

Volumn 153, Issue 4, 2007, Pages 544.e1-544.e8

  Botoni, Fernando A ^a,b   Poole Wilson, Philip A ^c   Ribeiro, Antonio L P ^a,b   Okonko, Darlington O ^c   Oliveira, Bráulio M R ^a   Pinto, Airandes S ^a   Teixeira, Mauro M ^a,b   Teixeira Jr , Antonio L ^a,b   Reis, Adelina M ^a,b   Dantas, Jackellyne B P ^a   Ferreira, Cid S ^a   Tavares Jr , Wilson C ^a   Rocha, Manoel Otávio C ^a,b  

^a University Hospital   (Brazil)

^b Fellow of the National Research Council   (Brazil)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; ENALAPRIL; PLACEBO; RANTES; SPIRONOLACTONE;

ADULT; ARTICLE; CHAGAS DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

EID: 33947328740     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.12.017     Document Type: Article

References (36)

1. Rocha M.O.C., Ribeiro A.L.P., and Teixeira M.M. Clinical management of chronic Chagas cardiomyopathy. Front Biosci 8 (2003) 44-54
2. Chagas disease. Disease Watch 2003. TDR/Nature Reviews Microbiology. Available at: http://www.who.int/tdr/dw/chagas2003.htm. Accessed October11,2005
3. Mady C., Cardoso R.H., Barretto A.c., et al. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation 90 (1994) 3098-3102
4. Dias E., Laranja F.S., and Nobrega G. Doença de Chagas. Mem Inst Oswaldo Cruz 42 (1945) 530-545
5. Bestetti R.B., and Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol 60 (1997) 187-193
6. Bogliolo L. As causas anatômicas da insuficiência cardíaca na cardiopatia (Miocardite) chagásica crônica estudadas comparativamente com as causas anatômicas da insuficiência cardíaca noutras cardiopatias. Arq Cardiol 29 (1976) 419-424
7. Braunwald E. Congestive heart failure: a half century perspective. Eur Heart J 22 (2001) 825-836
8. Coca S.G., and Perazella M.A. The role of aldosterone blockers in the management of chronic heart failure. Am J Med Sci 330 (2005) 176-183
9. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
11. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
12. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL. Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
13. Poole-Wilson P.A., Swedberg K., and Cleland J.G.F. A comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
14. Roberti R.R., Martinez E.E., et al. Chagas cardiomyopathy and captopril. Eur Heart J 13 (1992) 966-970
15. Khoury A.M., Davila D.F., et al. Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Int J Cardiol 57 (1996) 21-29
16. Dávila D.F., Angel F., Bellabarba G.A., et al. Effects of metoprolol in chagasic patients with severe congestive heart failure. Int J Cardiol 85 (2002) 255-260
17. Albuquerque C.D., Batlouni M., Rocha R.M., et al. ACORDES Trial-Brazilian open label study with carvedilol to demonstrate efficacy and chronic heart failure, including a pilot subgroup with Chagas' disease. J Cardiac Heart Fail 9 (2003) S58
18. Mckee P.A., Castelli W.P., et al. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 285 (1971) 1441-1446
19. Ware Jr. J.E. SF-36 health survey update. Spine 25 (2000) 3130-3139
20. Sahn D.J., De Maria A., Kisslo J., et al. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072
21. Schiller NB, Shah PM. Crawford M. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. 1989:2;358-367
22. Tei C. New noninvasive index for combined systolic and diastolic ventricular function. J Cardiol 26 (1995) 135-136
23. Milne E.N.C., Pistolesi M., Miniati M., et al. The vascular pedicle of the heart and the vena azygos in the normal subject. Radiology 152 (1984) 1-8
24. Milne E.N.C., Pistolesi M., Miniati M., et al. The radiologic distinction of cardiogenic and noncardiogenic edema. AJR Am J Roentgenol 144 (1985) 879-894
25. Altman D.F. Practical statistics for medical research. 1st ed. (1991), Chapman & Hall Editor
26. Gaibazzi N. Early detection by the Tei index of carvedilol-induced improved left ventricular function in patients with heart failure. Am J Cardiol 96 (2005) 467
27. Ribeiro A.L.P., Reis A.M., Barros M.V.L., et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 360 (2002) 461-462
28. Talvani A., Rocha M.O., Cogan J., et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz 99 (2004) 645-649
29. Frantz L.P., Olson L.J., Grill D., et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am J Heart 149 (2005) 541-547
30. Yoshizawa A., Yoshikawa T., and Nakamura I. Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure. J Card Fail 10 (2004) 310-315
31. Teixeira M.M., Gazzinelli R.T., and Silva J.S. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol 18 (2002) 262-265
32. Wolf G., Ziyadeh F.N., Thaiss F., et al. Angiotensin II stimulates expression of the chemokine in rat glomerular endothelial cells. J Clin Invest 100 (1997) 1047-1058
33. Leon S.J., Wang K., and Engman D.M. Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation 107 (2003) 2264-2269
34. Marino A.M.PN., Silva A., Santos P.V., et al. Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis. Circulation 110 (2004) 1443-1449
35. Hallsworth M.P., Twort C.H.C., Lee T.H., et al. β2 Adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 132 (2001) 729-741
36. Ohtsuka T., Hamada M., Hiasa G., et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. JAAC 37 (2001) 412-417